HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: These results suggest that the combination of a JAK inhibitor and HDAC inhibitor had a strong synergistic anti-tumor effect in CTCL cell lines and may represent a promising novel therapeutic modality for CTCL patients.